Original Article

Community-acquired Pneumonia: Compliance with Centers for Medicare and Medicaid Services, National Guidelines, and Factors Associated with Outcome

Authors: D. Randall Ziss, PHARMD, BCPS, FASHP, Allan Stowers, RPH, MS, Carinda Feild, PHARMD

Abstract

Background This study was performed to evaluate the impact of adherence to national guidelines for management of community-acquired pneumonia (CAP) on patient outcomes. Methods Compliance with published national guidelines was assessed. Mortality rate and length of hospital stay were determined. Results Patients who were administered antibiotics within 4 hours of admission had a shorter stay. Those treated at least 8 hours after admission had the highest mortality. Good compliance seen with 1998 guidelines of the Infectious Diseases Society of America declined substantially when 2000 Infectious Diseases Society of America guidelines were evaluated. Pediatric compliance was difficult to evaluate. Documentation of vaccination screening and administration was poor. Conclusion Antibiotic therapy should be started within 4 hours in patients with CAP. Using the most recent CAP guidelines as a benchmark may lower compliance unless providers are reeducated. National consensus guidelines for pediatric patients should be developed. Hospitals should evaluate documentation of vaccine screening and administration and should implement programs to increase vaccination rates if needed.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. National Institute of Allergy and Infectious Diseases. Community-acquired pneumonia in adult and elderly populations. Clin Courier 1999; 16 (55): 1–16(CME).
 
2. Bartlett JG, Breiman RF, Mandell LA, File TM Jr. Community-acquired pneumonia in adults: Guidelines for management—The Infectious Diseases Society of America. Clin Infect Dis 1998; 26: 811–838.
 
3. Fedson DS. Pneumococcal vaccination in the prevention of community-acquired pneumonia: An optimistic view of cost-effectiveness. Semin Respir Infect 1993; 8: 285–293.
 
4. Heffron R. Pneumonia, with Special Reference to Pneumococcus Lobar Pneumonia. Cambridge, MA, Harvard University Press, 1979.
 
5. Bullows JGM. The reliability of sputum typing and its relation to serum therapy. JAMA 1935; 105: 1512–1518.
 
6. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impact. Am J Med 1985; 78: 32–37.
 
7. Marston BJ, Plouffe JF, Breiman RF, et al. Preliminary findings in a community-based pneumonia incidence study, in Barbaree JM, Breiman RF, Dufour AP (eds): Legionella: Current Status and Emerging Perspectives. Washington, DC, American Society for Microbiology, 1993, pp 36–37.
 
8. Niederman MS, McCombs JS, Unger AN, Kumar A, Popovian R. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820–837.
 
9. American Thoracic Society. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993; 148: 1418–1426.
 
10. Murphy SL. Deaths: Final data for 1998. Natl Vital Stat Rep 2000; 48 (11): 1–105.
 
11. Nathwani D, Rubinstein E, Barlow G, Davey P. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001; 32: 728–741.
 
12. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults: Infectious Diseases Society of America. Clin Infect Dis 2000; 31: 347–382.
 
13. Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance: A report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399–1408.
 
14. Niederman MS, Mandell LA, Anzueto A, Bass JB, Broughton WA, Campbell GD, et al. Guidelines for the management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730–1754.
 
15. Jadavji T, Law B, Lebel MH, Kennedy WA, Gold R, Wang EE. A practical guide for the diagnosis and treatment of pediatric pneumonia. CMAJ 1997; 156: S703–S711.
 
16. Meehan TP, Fine MJ, Krumholz HM, Scinto JD, Galusha DH, Mockalis JT, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080–2084.
 
17. Yih JY, Black SA, Beck CK. Retrospective evaluation of the management and outcomes in hospitalized patients with community acquired pneumonia applying an outcome prediction score. Abstracts of the ASHP Clinical Mid-year Meeting, December 3–7, 2001, New Orleans, LA.
 
18. Amberik JC, Cummings TL. Impacting patient outcomes in hospitalized patients with community acquired pneumonia. Abstracts of the ASHP Clinical Mid-year Meeting, December 3–7, 2001, New Orleans, LA.
 
19. Marston BJ, Plouffe JF, File TM Jr, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio—The Community-Based Pneumonia Incidence Study Group. Arch Intern Med 1997; 157: 1709–1718.
 
20. Atlas Scoring: A Technical White Paper. Westborough, MA, MediQual Systems, Feb 1996.
 
21. Kahn KL, Rogers WH, Rubenstein LV, Sherwood MJ, Reinisch EJ, Keeler EB, et al. Measuring quality of care with explicit process criteria before and after implementation of the DRG-based prospective payment system. JAMA 1990; 264: 1969–1973.
 
22. McGarvey RN, Harper JJ. Pneumonia mortality reduction and quality improvement in a community hospital. QRB Qual Rev Bull 1993; 19: 124–130.
 
23. Mandell LA. Antibiotic therapy for community-acquired pneumonia. Clin Chest Med 1999; 20: 589–598.
 
24. Gordon GS, Throop D, Berberian L, et al. Validation of the therapeutic recommendations of the American Thoracic Society guidelines for community-acquired pneumonia in hospitalized patients, in Abstracts of the CHEST World Congress, October 27–31, 1996, San Francisco, CA.
 
25. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837–1842.
 
26. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562–2572.
 
27. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333: 1618–1624.
 
28. Gay K, Baughman W, Miller Y, Jackson D, Whitney CG, Schuchat A, et al. The emergence ofStreptococcus pneumoniae resistant to macrolide antimicrobial agents: A 6-year population-based assessment. J Infect Dis 2000; 182: 1417–1424.
 
29. Chen DK, McGeer A, de Azavedo JC, Low DE. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233–239.